Video

Certara Pinnacle 21 Enterprise Plus – SDTM mapping specifications

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Mapping clinical data to CDISC SDTM is mandatory for clinical trial submissions. But accurately mapping…

Danielle PillsburyMarch 31, 2026

Blog

Platforms for collaboration between sponsors and CROs: 5 ways CROs can scale efficiently while maximizing validation assurance

Platforms for collaboration between sponsors and CROs provide validation assurance & improve sponsor outcomes with…

CertaraMarch 31, 2026

Blog

Data Fabrics in Pharma: Connecting Data for Better Decisions

Learn how a data fabric in pharma connects siloed systems. Explore the benefits of data…

CertaraMarch 31, 2026

On-Demand Webinar

Pinnacle 21 Community vs Enterprise: Watch the webinar to decide what’s right for your study

Watch the Pinnacle 21 Community vs Enterprise webinar to learn key considerations for validation approaches…

CertaraMarch 27, 2026

Press Coverage Video

How Bayesian Design Is Reshaping Clinical Development

Learn how Bayesian design is reshaping clinical trials with adaptive methods that improve efficiency, reduce…

CertaraMarch 27, 2026

Blog Knowledge Base

Where Did the 80-125% Bioequivalence Criteria Come From?

Discover what bioequivalence criteria mean, why the 80-125% bioequivalence range is used, and how custom…

CertaraMarch 27, 2026

Case Study

Integrated PK/PD Modeling and Machine Learning to Support CNS Compound Selection

PK/PD Modeling for CNS drug development using Phoenix NLME and machine learning for better CNS…

CertaraMarch 26, 2026

Publication

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

This review article examines the development of radiopharmaceutical imaging agents and radioligand therapies for pediatric…

CertaraMarch 26, 2026

Blog

Shaping the Future of Medical Writing: Key Themes for 2026

Five key themes and their implications for leaders shaping their Medical Writing strategy for 2026

CertaraMarch 26, 2026

eBook

The Next Lap in Global Regulatory Submission Speed: Advanced Approaches to Excellence and Acceleration

Discover advanced regulatory writing strategies, global regulatory submission best practices, eCTD guidance, ICH M15 updates…

CertaraMarch 26, 2026

Certara Pinnacle 21 Enterprise Plus – SDTM mapping specifications

Platforms for collaboration between sponsors and CROs: 5 ways CROs can scale efficiently while maximizing validation assurance

Data Fabrics in Pharma: Connecting Data for Better Decisions

Pinnacle 21 Community vs Enterprise: Watch the webinar to decide what’s right for your study

How Bayesian Design Is Reshaping Clinical Development

Where Did the 80-125% Bioequivalence Criteria Come From?

Integrated PK/PD Modeling and Machine Learning to Support CNS Compound Selection

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

Shaping the Future of Medical Writing: Key Themes for 2026

The Next Lap in Global Regulatory Submission Speed: Advanced Approaches to Excellence and Acceleration

Newsletter sign up

Quick links

Solutions

Contact